Trial · NCT00536263
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss | 24 weeks after end of treatment (EOT) | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With HBeAg Loss | Up to Treatment Week 48 | Treated participants | Participants | NUMBER |
| SECONDARY | HBe Seroconversion | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With HBV-DNA < 200 IU/mL | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With HBV-DNA Undetectable | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With Biochemical Response | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Number of Participants With Combined Response | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Hepatitis B Surface Antigen (HBsAg) Loss | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Hepatitis B Surface Antigen (HBs) Seroconversion | End of treatment (EOT) and 24 weeks after EOT | Treated participants | Participants | NUMBER |
| SECONDARY | Change From Baseline in Liver Biopsy Score | Baseline to 24 weeks after end of treatment | Treated participants from designated sites | Units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00536263/outcomes